(Q35029719)

5 August 2017

1 reference

title

Nail disorders: unapproved treatments (English)

1 reference

5 August 2017

Joseph Obadiah

1

1 reference

5 August 2017

Richard Scher

series ordinal

2

1 reference

5 August 2017

publication date

1 November 2002

1 reference

5 August 2017

published in

Clinics in Dermatology

1 reference

5 August 2017

volume

20

1 reference

5 August 2017

issue

6

1 reference

5 August 2017

page(s)

643-648

1 reference

Onychomycosis: therapeutic update

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Current management of onychomycosis. An overview

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Onychomycosis. Agents of choice.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Levels of fluconazole in serum, stratum corneum, epidermis-dermis (without stratum corneum) and eccrine sweat

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Posttreatment itraconazole levels in the nail. New implications for treatment in onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

An evaluation of intermittent therapies used to treat onychomycosis and other dermatomycoses with the oral antifungal agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Nail incorporation kinetics of terbinafine in onychomycosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Treatment of Candida nail infection with terbinafine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Onychomycosis due to Scopulariopsis brevicaulis: clinical features and response to systemic antifungals.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Terbinafine in onychomycosis with involvement by non-dermatophytic fungi

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: A multicenter study with 36 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Onychomycosis in children: prevalence and management

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Onychomycosis in children: prevalence and treatment strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Ciclopirox nail lacquer solution 8% in the 21st century

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Preclinical data and mode of action of amorolfine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Amorolfine in the treatment of onychomycoses and dermatomycoses (an overview)

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Amorolfine and itraconazole combination for severe toenail onychomycosis; results of an open randomized trial in Spain.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Tioconazole nail solution--an open study of its efficacy in onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

The topical treatment of onychomycosis using a new combined urea/imidazole preparation

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Treatment of Onychomycosis by Partial Nail Avulsion and Topical Miconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Treatment of onychomycosis with nail avulsion and topical ketoconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Treatment of onychomycosis by ODT therapy with 20% urea ointment and 2% tolnaftate ointment

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Efficacy of a surfactant, allantoin, and benzalkonium chloride solution for onychomycosis. Preliminary results of treatment with periodic debridement

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Management of toenail onychomycosis with 2% butenafine and 20% urea cream: a placebo-controlled, double-blind study.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Management of nail psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Topical ciclosporin in nail psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Topical anthralin therapy for refractory nail psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

A simplified protocol of steroid injection for psoriatic nail dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Response of psoriatic nails to oral photochemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Local PUVA treatment for nail psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Dynamics of psoriatic trachyonychia during low-dose cyclosporin A treatment: a pilot study on onychochronobiology using optical profilometry

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

A 12-month treatment of severe psoriasis with acitretin: Results of a Canadian open multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900285-7

7 January 2021

10.1016/S0738-081X(02)00285-7

Identifiers

DOI

1 reference

5 August 2017

1 reference